Our principal expertise lies in the modification of natural organisms and macromolecules to enhance their therapeutic potency, safety and delivery kinetics. In particular, we have world leading expertise in the field of oncolytic vaccines.
PsiOxus was formed in 2010 through the acquisition of Hybrid Biosystems by Myotec Therapeutics.
Hybrid Biosystems was formed in 2000, based upon the ground-breaking CRUK funded research of Professor Len Seymour and Dr Kerry Fisher, now both at Oxford University, into the optimisation of viruses as therapeutic agents. ColoAd1 is the lead clinical stage program from this work, with the research programs PSI-001, PolySTAR, PolyMAP following closely behind.
Myotec was formed in 2006 as an Imperial College spin out company based upon the world leading research of Professor Stefan Anker and Professor Andrew Coats into the underlying mechanisms of cachexia across a wide range of chronic disease states. MT-102 is the lead clinical stage program from this work.